Additional information
White powder
139481-72-4
ACI-032124
184.1-186.9°C
C43H34N6O3
682.77
cold Condition
-20°C
Hypertension
Pharmaceutical Impurity Standards
2-Ethoxy-1-[[2`-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1`-biphenyl]-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid (N-Trityl candesartan)
2-Ethoxy-1-[(2?-(1-trityl-1H-tetrazol-5-yl)-1,1?-biphenyl-4-yl)methyl]-7-benzimidazolecarboxylic acid Candesartan-trityl candesartan
Candesartan-trityl candesartan






![Ethyl (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethylsulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate](https://staging.analyticachemie.in/wp-content/uploads/1A06130-150x150.png)


![2-sec-butyl-4-{4-[4-(4-methoxyphenyl)piperazin-1-yl]phenyl}-2H-1,2,4-triazol-3(4H)-one](https://staging.analyticachemie.in/wp-content/uploads/1A06380-150x110.png)
![Abiraterone Isopropyl Ether (25 mg) (3-((3S,8R,9S,10R,13S,14S)-3-isopropoxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)pyridine; 3beta-Isopropoxy-17-(pyridin-3-yl)androsta-5,16-diene)](https://staging.analyticachemie.in/wp-content/uploads/image-1-150x145.png)